A familiar complaint inside Europe’s research ministries goes something like this: the continent trains world-class scientists, funds excellent basic research, and then watches the resulting breakthroughs get commercialised somewhere else. The European Commission now wants to do something concrete about that gap, and 2026 is shaping up as the year it tries.
Two pieces of legislation are converging on the same problem from different angles. The European Research Area Act, originally pencilled in for 2027, has been pulled forward at the insistence of research commissioner Ekaterina Zaharieva so that it can clear the legislative process before the current Commission’s mandate ends. A public consultation that closed in January drew 735 submissions and 117 position papers from all 27 member states, eight countries associated with Horizon Europe, and fifteen others beyond the bloc, a response rate that signals how badly stakeholders want Brussels to act. The Commission is expected to table its proposal in the third quarter of the year.
The ERA Act’s ambition is structural. It would set binding minimum standards for how researchers build careers, are hired, and move between institutions and countries, an attempt to dissolve the patchwork of national rules, pension systems and contract types that has long made it harder for a scientist to relocate within the EU than to leave it altogether for the United States. Mobility has been a stated EU priority for two decades; what is new is the willingness to make some of it legally binding rather than aspirational.
Running alongside it is the European Innovation Act, aimed less at researchers and more at the businesses trying to turn research into products. Zaharieva has described it as a vehicle to simplify and streamline the regulatory thicket that start-ups and scale-ups face when moving from prototype to market, covering everything from technology transfer rules to access to venture capital to the testing of new products under real-world conditions. The European Parliament has welcomed the framing, which matters because both files will need parliamentary buy-in to move quickly.
The political logic behind doing both at once is that Europe’s innovation problem has never been purely about money, though the funding gap with the United States and China is real and widely cited. It is also about friction: a researcher who cannot easily move, a small firm that cannot easily test a new device across borders, an investor who faces twenty-seven different sets of rules for essentially the same activity. Tackling research mobility and market access in parallel is meant to address both halves of the pipeline rather than just the funding tap at the start of it.
The risk, as with most reform packages in Brussels, is that ambition outruns delivery. The EU has produced strategy documents on research fragmentation for years without changing much on the ground, and member states have historically guarded their own systems for hiring scientists and regulating new technologies. Binding obligations are harder to ignore than recommendations, but they are also harder to negotiate, and the consensus-driven politics of research policy mean some provisions could be watered down before they reach the statute book.
What makes this round different is the deliberate pairing of two files that touch the entire chain from lab bench to balance sheet, backed by a consultation response that suggests stakeholders are tired of waiting. Whether that translates into a law researchers and entrepreneurs actually notice will become clear once the Commission’s text lands later this year.
